… study aimed to compare erlotinib (E) and etoposide/cisplatin (EP) with concurrent radiation
therapy (RT) for patients with stage IIIA/B unresectable advanced non-small cell lung cancer …

… is quite challenging in treating most types of cancer. Herein, we report the synthesis of
antibody linked fibrin nanoparticles for the treatment of non-small cell lung cancer (NSCLC). Wet …

… tissues were further analyzed by the histological studies and immunohistochemical assay. …
tumor cells for the 6 × 6 × 64 nt-Er treated group. TUNEL staining verified more apoptotic cells …

… By using a population PK approach, the aims of the present study were to describe the PK
profile of erlotinib in adult patients with NSCLC from a real-world setting, to identify factors …

… In the present study we followed up on K Ca 3.1 channels … in erlotinib-ressitance of NSCLC
cells using the A549-3R cell … cells, we generated partially erlotinib-resistant A549-3R cells …

… If 1 or more patients had an objective response, the study was to continue enrollment to the
… This study also obtained a tumor growth estimate for patient's disease on the last erlotinib-…

… In conclusion, the present study reports a complex and diversified tumor evolution under
erlotinib treatment, by phenotypic transformation from ADC to SCLC with the acquisition of a …

… , 12-15 whereas other studies failed to demonstrate any PFS benefit. Thus, this study aimed
to … , bevacizumab, with the EGFR-TKI, erlotinib, in improving clinical outcomes in previously …

… reported to contribute to erlotinib resistance in non-small-cell lung cancer (NSCLC) through
… -TKIs in erlotinib-resistant NSCLC HCC827 (HCC827/ER) cells remain unknown. This study …

… in TKI-resistance lung cancer cells could reverse the resistant phenotype in tumor cells,
thereby … Research work was aimed to address the following key problems associated with …